-continued

<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 110

cttggttatg ttggcactga tc 22

<210> SEQ ID NO 111
<211> LENGTH: 22
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 111

tgtgttaggg gactggtgga ca 22

<210> SEQ ID NO 112
<211> LENGTH: 22
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 112

catcacccac ttacccccaa aa 22

<210> SEQ ID NO 113
<211> LENGTH: 22
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 113

ataaccgagt cgttctgcca at 22

<210> SEQ ID NO 114
<211> LENGTH: 22
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 114

tttcagagca ttggccatag aa 22

What is claimed is:

1. A method for treating or preventing cancer in a subject in need thereof comprising administering to the subject an amount of nicotinamide mononucleotide (NMN), or a salt thereof, or a prodrug thereof, effective to increase the level of nicotinamide adenine dinucleotide (NAD+) in the subject.

2. The method of claim **1**, wherein the NMN or salt thereof, or prodrug thereof, is administered at a dose of between 0.5-5 grams per day.

3. The method of claim **1**, wherein the subject is a human.

4. The method of claim **1**, wherein the NMN or salt thereof, or prodrug thereof, is administered as a pharmaceutical composition comprising a pharmaceutically acceptable carrier and the NMN or salt thereof, or prodrug thereof.

5. The method of claim **4**, wherein the pharmaceutical composition is adapted for oral administration.

6. The method of claim **1**, wherein the NMN or salt thereof, or prodrug thereof, is administered orally.

7. The method of claim **2**, wherein the NMN or salt thereof, or prodrug thereof, is administered orally.

8. The method of claim **4**, wherein the NMN or salt thereof, or prodrug thereof, is administered orally.

9. The method of claim **2**, wherein the subject is a human.

10. The method of claim **4**, wherein the subject is a human.

11. The method of claim **5**, wherein the subject is a human.

12. The method of claim **2**, wherein the NMN or salt thereof, or prodrug thereof, is administered as a pharmaceutical composition comprising a pharmaceutically acceptable carrier and the NMN or salt thereof, or prodrug thereof.

13. The method of claim **12**, wherein the pharmaceutical composition is adapted for oral administration.

14. The method of claim **12**, wherein the NMN or salt thereof, or prodrug thereof, is administered orally.

15. A method for treating or preventing cancer in a subject in need thereof, comprising administering to the subject an amount of NMN, or a salt thereof, effective to increase the level of NAD+ in the subject.